Article
Gastroenterology & Hepatology
Nathaniel A. Cohen, Maryam Zafer, Namrata Setia, Michael J. Anderson, Atsushi Sakuraba, Sushila Dalal, Joel Pekow, Russell D. Cohen, David T. Rubin, Dejan Micic
Summary: This study found that serum CMV PCR can be used as a non-invasive test for diagnosing CMV colitis in UC patients, and it has excellent negative predictive value and a strong correlation with CMV positivity on histology.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
David Laharie, Arnaud Bourreille, Julien Branche, Matthieu Allez, Yoram Bouhnik, Jerome Filippi, Frank Zerbib, Guillaume Savoye, Lucine Vuitton, Jacques Moreau, Aurelien Amiot, Laurent Beaugerie, Elena Ricart, Olivier Dewit, Antonio Lopez-Sanroman, Mathurin Fumery, Franck Carbonnel, Anthony Buisson, Benoit Coffin, Xavier Roblin, Gert van Assche, Maria Esteve, Martti Farkkila, Javier P. Gisbert, Philippe Marteau, Stephane Nahon, Martine de Vos, Laurent Peyrin-Biroulet, Jean-Yves Mary
Summary: In patients with steroid-refractory ASUC responding to second-line medical therapy, the process of endoscopic remission started with bleeding remission and was not achieved in half the patients at day 98 for vascular pattern. Infliximab provided a higher endoscopic remission rate than cyclosporine at day 98.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Review
Immunology
Fengqin Zhu, Zongjing Hu, Wei Yu, Fengxian Dai, Dehuai Jing, Guangxi Zhou
Summary: This case report describes a patient with ulcerative colitis (UC) who developed cytomegalovirus (CMV) infection and bullous Sweet's syndrome (a cutaneous extra-intestinal manifestation of UC) after treatment. The patient subsequently developed acute myeloid leukemia (AML) and died.
JOURNAL OF INFLAMMATION RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Dan Liu, Ran Zhao, Yajing Wu, Yunhong Wang, Rongping Yang, Xiumei Ke
Summary: Scutellaria-Coptis decoction can effectively alleviate ulcerative colitis and improve the diversity and composition of intestinal microbiota.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Alix Demaris, Ella S. K. Widigson, Johan F. K. F. Ilvemark, Casper Steenholdt, Jakob B. Seidelin, Wilhelm Huisinga, Robin Michelet, Linda B. S. Aulin, Charlotte Kloft
Summary: This review aims to analyze the population PK models of infliximab (IFX) in patients with ulcerative colitis (UC) and acute severe UC (ASUC), and assess the impact of disease activity on IFX PK. The results showed that there are still many gaps in the current research, such as a limited number of models specifically developed for UC patients, a lack of studies on severe UC patients, and a lack of evaluation of predictive performance for the models. Therefore, more comprehensive research and adequate reporting and evaluation of the models are needed for clinical application.
Review
Medicine, General & Internal
Yafei Qin, Grace Wang, Dejun Kong, Guangming Li, Hongda Wang, Hong Qin, Hao Wang
Summary: CMV reactivation in patients with ulcerative colitis (UC) is significantly associated with disease severity, pancolitis, older age of UC onset, and the use of glucocorticoids, immunosuppressants, and azathioprine. However, infliximab treatment does not increase the risk of CMV reactivation, while 5-aminosalicylic acid is linked to a lower risk. Monitoring for these risk factors is crucial for timely diagnosis and treatment in UC patients.
Article
Gastroenterology & Hepatology
Na Li, Peiguang Ma, Yalan Li, Xuekai Shang, Xinmei Nan, Lei Shi, Xiao Han, Jiajing Liu, Yanfei Hong, Qiuyi Li, Jiaqi Cui, Junxiang Li, Guiying Peng
Summary: Intestinal microbiota dysbiosis and metabolic disruption are well-known triggers of ulcerative colitis. However, their role in regulating ILC3s, which are crucial for intestinal health, has not been explored. This study found that the microbiota structure of severe UC patients differed from those with mild UC, moderate UC, and healthy controls. Microbes producing secondary bile acids decreased with the worsening of UC, and there was a strong positive correlation between them. The study also showed that microbiota-mediated inflammatory modulation increased with disease severity, leading to reduced ILC3 percentage and down-regulated bile acid receptor expressions.
Article
Gastroenterology & Hepatology
Tsukasa Yamawaka, Hiroki Kitamoto, Masanori Nojima, Tomoe Kazama, Kohei Wagatsuma, Keisuke Ishigami, Shuji Yamamoto, Yusuke Honzawa, Minoru Matsuura, Hiroshi Seno, Hiroshi Nakase
Summary: In this study, we analyzed the associations among histopathological tests, antigenemia assays, and mucosal PCR in UC patients with HCMV colitis. The HCMV-DNA copy number in colonic tissues was significantly associated with positive immunohistochemistry and antigenemia results. A cutoff value of 1300 copies/μg of HCMV-DNA was determined to predict positive antigenemia results. Additionally, the HCMV-DNA copy number correlated with the total UCEIS score and bleeding score, indicating its potential use in diagnosing HCMV colitis in UC patients.
JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Raffi Lev-Tzion, Gili Focht, Rona Lujan, Adi Mendelovici, Chagit Friss, Shira Greenfeld, Revital Kariv, Amir Ben-Tov, Eran Matz, Daniel Nevo, Yuval Barak-Corren, Iris Dotan, Dan Turner
Summary: COVID-19 vaccine effectiveness in IBD patients is comparable to non-IBD controls and is not affected by treatment with TNF inhibitors or corticosteroids. The risk of IBD exacerbation did not differ between vaccinated and unvaccinated patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Alex Adams, Vipin Gupta, Waled Mohsen, Thomas P. Chapman, Deloshaan Subhaharan, Pradeep Kakkadasam Ramaswamy, Sudheer Kumar, Saurabh Kedia, Colleen G. C. McGregor, Tim Ambrose, Bruce D. George, Rebecca Palmer, Oliver Brain, Alissa Walsh, Vineet Ahuja, Simon P. L. Travis, Jack Satsangi
Summary: The changes in acute severe colitis (ASC) management have resulted in improved outcomes. A simple predictive model can be used to identify patients who will not respond to steroids upon admission.
Article
Immunology
Jing Yang, Xin Guan, Simeng He, Lixiu Ge, Qiaoying Gao, Xiaoyang Wu
Summary: The study investigates the protective influence of FTY720 on inflammation in a DSS-induced colitis model. The results demonstrate that FTY720 improves the aberrant immune response by trapping T cells and inhibiting the polarization of M1 macrophages in colitis mice. Additionally, the depletion of CCR2 does not affect the protective effect of FTY720 on colonic injury.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Joshua Kwon, Daniela Fluxa, Francis A. Farraye, Paul T. Kroner
Summary: The study found a significant association between IBD and CMV colitis, with a higher occurrence rate in patients with UC. Patients with CD and CMV colitis had increased odds of mortality, shock, and ICU stay, while patients with UC had a higher likelihood of undergoing colectomy. Patients with IBD and CMV colitis also experienced higher odds of acute kidney injury, multiorgan failure, increased hospital costs, and longer hospital stays compared to those without CMV colitis. Prospectively designed studies are needed to further investigate the risk factors and impact of CMV colitis on IBD patients.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2022)
Review
Gastroenterology & Hepatology
Brigida Barberio, Christopher J. Black, Edoardo Savarino, Alexander C. Ford
Summary: The study found that both ciclosporin and infliximab were superior to placebo in terms of improving treatment response and avoiding colectomy in patients with acute glucocorticosteroid-refractory ulcerative colitis, with no significant differences in efficacy or safety between the two within 1 year.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Cell Biology
Abigail R. Cannon, Esther H. Shim, Paulius Kuprys, Mashkoor A. Choudhry
Summary: Ulcerative colitis (UC) is a disease characterized by cycles of active flare and remission. Alcohol has been found to increase the severity of UC pathology. This study investigated the effects of alcohol on IL-22 expression and whether recombinant IL-22 or probiotic treatment could alleviate UC symptoms. The results showed that treatment with rIL-22 and Lactobacillus delbrueckii can attenuate UC exacerbation and increase IL-22 levels.
JOURNAL OF LEUKOCYTE BIOLOGY
(2022)
Review
Medicine, General & Internal
Benjamin L. Gordon, Robert Battat
Summary: Therapeutic drug monitoring (TDM) is a useful strategy in ulcerative colitis (UC), particularly in acute severe UC (ASUC). While there is limited data available for the use of TDM of infliximab in ASUC, observational data suggest that higher serum infliximab concentrations and lower clearance are associated with better clinical outcomes and decreased rates of colectomy. However, more studies are needed to evaluate optimal dosing and TDM targets in this population.
JOURNAL OF CLINICAL MEDICINE
(2023)
